 Home >

Medical News

Home



Latest Medical News

Shangjian Bio-CD38/CD47 double antibody was approved for clinical use in the U.S.

 Time of Update: 2022-01-15

It is worth mentioning that, based on the BIMA double antibody platform, Sunkin Bio has also developed a number of "1+1>2" double antibody projects, two of which have been approved for clinical use .
100 million yuan down payment!

 Time of Update: 2022-01-15

experimental research results of CM326 in the Phase 1 clinical study of healthy volunteers, Chengdu Conoya will rapidly advance the clinical trials of CM326 for various indications . At present, CM326
Targeting CLDN 18.2!

 Time of Update: 2022-01-15

According to the press release of Keji Pharmaceuticals, CT041 has been approved by the US FDA, China National Medical Products Administration (NMPA) and Health Canada to conduct clinical trials .
Which product is the hottest product on the new crown track is expected to become a blockbuster?

 Time of Update: 2022-01-15

crown vaccines in five ways, from the most traditional inactivated vaccines (represented by Kexing and Sinopharm), to adenovirus vaccines (such as AstraZeneca and Johnson & Johnson), and attenuated influenza viruses Vector vaccines, recombinant
The selection criteria for dual-channel pharmacies are here!

 Time of Update: 2022-01-14

a "biological product" business scope, while Hebei Province emphasizes the establishment of a special business area for negotiating drugs, with an area of more than 40 square meters, including independent drug fields. in warehousing
How is the transformation of Bigpharma's CSPC Group?

 Time of Update: 2022-01-14

Source: Zhongkang FIC Intelligence database02 "Creation + imitation" dual engine accelerates to seize the market02 "Creation + imitation" dual engine accelerates to seize the marketIn recent years, CSPC has continuously increased R&D investment, focusing on R&D and innovation .
Hengrui people have license in. Who will find the new drug king?

 Time of Update: 2022-01-14

-2. 5. Naturally, regulators cannot agree . >At the first point, the Red Sea target may have been selected on the Red Sea Circuit. As for whether
Alis Medical's third-generation EGFR-TKI plans to be included in breakthrough treatment products

 Time of Update: 2022-01-14

ArticleMedicine Guanlan>On November 23, the Center for Drug Evaluation (CDE) of the National Medical Products Administration of China announced that the third
The multi-target inhibitor introduced by Zai Lab over US$350 million received clinical approval for the first time

 Time of Update: 2022-01-14

/>. >TPX-0022 is an oral multi-target kinase inhibitor targeting MET and related cancer signaling pathways SRC and CSF1R . In January this year
BeiGene's TYK2 inhibitor enters the clinic and expands its layout in the field of inflammation and immunology

 Time of Update: 2022-01-14

On November 22, 2021, BeiGene announced that the first patient in a phase 1 clinical trial of the potent tyrosine kinase 2 (TYK2) inhibitor BGB-23339 under investigation has been administered .

Medical World News

The U.S. Drug Administration approves emergency use of the second oral drug for the treatment of COVID-19

 Time of Update: 2022-01-10

>women during pregnancy . Common side effects of this drug may include diarrhea, nausea, and dizziness . </span
"Fourteenth Five-Year Plan" announces continued efforts in the field of high-end medical devices

 Time of Update: 2022-01-09

In the next five years, these medical devices, core components and key technologies will focus on advancing:
Interpretation of the "Fourteenth Five-Year" Medical Equipment Industry Development Plan

 Time of Update: 2022-01-09

medical-industrial collaboration and enhance effective supply capabilities . Strengthen demand traction, deepen supply-side structural reforms, build a medical-enterprise cooperation platform
Internet medical care is far from mature, cooperation must be greater than game

 Time of Update: 2022-01-09

Since everyone comes for the transformation and service of entities, then each other It is a kind of extensive cooperation, rather than a close dependency relationship, which gives these new Internet+ development models a large room for survival and development.
More than 10,000 drugs are suspended online, Pfizer involved in multiple blockbuster products

 Time of Update: 2022-01-09

com, the terminal chemical drug market of physical pharmacies in key cities in 2020 will exceed 50 billion yuan, of which atorvastatin calcium tablets top the list with 1.
Dongyang Sun Pharmaceutical will win 2.5 billion anti-ED drug-Sildenafil

 Time of Update: 2022-01-09

　　Recently, the official website of NMPA shows that Dongyang Pharmaceutical has entered the administrative examination and approval stage with the imitation of sildenafil citrate tablets reported
Ministry of Agriculture and Rural Affairs announced 100 national planting industry "three products and one standard" bases

 Time of Update: 2022-01-09

　　Recently, the Ministry of Agriculture and Rural Affairs announced the first batch of national planting industry "three products and one standard" bases. After the recommendation
There may be 32 blockbusters in 2021!

 Time of Update: 2022-01-09

According to data from Meinenet, in the first three quarters of 2021, public hospitals in key provinces and cities in China used more than 170 billion yuan of drugs, an increase of 12.
The market is heading towards 70 billion!

 Time of Update: 2022-01-09

China approved the import of dulaglutide injection (pre-filled injection pen) in February 2019, with the trade name Duyida, for blood sugar control in adult patients with type 2 diabetes .
Internet hospitals should promote the integration of online and offline services

 Time of Update: 2022-01-09

The report pointed out that as a new thing, the development and growth of Internet hospitals have brought certain impacts on patients, medicine, medical insurance and other parties, including opportunities and challenges .

Medical Research Articles

Nafuraphine Hydrochloride Orally Disintegrating Tablet, a joint product of 3SBio and Toray of Japan, submitted a marketing application

 Time of Update: 2022-01-11

disintegrating tablets (R&D code: TRK-820, Japanese brand name "REMITCH ® ") has been accepted, and it is used to improve the pruritus of hemodialysis patients whose curative effect
The BIPS2021 Global Biomedical Innovation Pioneer China Summit was successfully held in Shanghai

 Time of Update: 2022-01-11

Hui Aimin, Executive President and Global R&D Director of Fosun Pharma, gave a speech on the international development strategy of China's innovative drugs, and shared Fosun Pharma’s clinical needs-oriented R&D strategy and the practice of R&D innovation and internationalization.
WHO approves Novavax vaccine to re-enter emergency use list

 Time of Update: 2022-01-11

>) the World Health Organization into emergency use list Nuvaxovid be admitted into the emergency use of the list
Eddie Pharmaceuticals and PerkinElmer reached a strategic cooperation

 Time of Update: 2022-01-11

At the same time, the two parties will carry out clinical research and market development cooperation on the diagnosis and treatment of AIDS .
Cell Industry Conference 2022 conference plan is released: April Shanghai, August Shenzhen, November Wuhan, looking forward to your joining!

 Time of Update: 2022-01-11

clearly identify specific cells and their functions . >>Cell and gene therapy have changed the way human beings treat genetic diseases
Yuyue Medical won the "2021 First Financial Innovation Competitive Enterprise" Innovation-driven high-quality development

 Time of Update: 2022-01-10

Yuyue Medical won the "2021 CBN Innovation Competitive Enterprise" award In the past eight years, CBN has visited hundreds of listed companies in depth, creating and perfecting an evaluation model for continuous innovation .
Everyone Insurance: China’s basic pension has experienced 17 consecutive increases, but pensions need to pay attention to these

 Time of Update: 2022-01-10

Close to medical care, close to children, old-age care and more love for the city centerWhen it comes to the retirement community, many elderly people show concern .
Luye Pharma's new antidepressant drug Ansufaxine Hydrochloride Sustained-Release Tablets Phase II Clinical Data Released

 Time of Update: 2022-01-10

), norepinephrine (NE) and dopamine (DA). Completed Phase I to Phase III clinical trials in China and is in the stage of market application . >The phase II clinical trial data released
Corning Jerry KN046 completed a phase II registration clinical trial for the first patient in the United States

 Time of Update: 2022-01-10

that the company's self-developed PD-L1/CTLA-4 double antibody KN046 completed the first patient in the United States Medicine . >The ENREACH-Thymic enrolled patients is a phase II
Lion Biotech obtained FDA Fast Track Certification: Application of HBV-specific TCR-T in the treatment of hepatocellular carcinoma

 Time of Update: 2022-01-10

prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.

Medical Science News

Within 1 week, 7 new drugs of this pharmaceutical company were applied for clinical application and marketing

 Time of Update: 2022-01-10

On December 24, the clinical application of Hengrui Medicine's 2 Class 1 new drugs was accepted by CDE, namely SHR-1816 injection and SHR-1501 for injection; in addition, the first company submitted 10% fat emulsion (OO )/5.
This pharmaceutical company has completed hundreds of millions of yuan in financing, and it is expected that 2-3 products will be approved for listing each year in the next 3 years

 Time of Update: 2022-01-10

Many of the company's projects are gradually entering phase III clinical trials, which will bring China's self-developed international-level respiratory preparations to the domestic market .
This pharmaceutical company raised US$120 million to develop innovative treatments for diabetes

 Time of Update: 2022-01-10

It is worth mentioning that the first product of Yinnuo Medicine is an innovative diabetes drug-Suparutide (long-acting human GLP-1), which is currently undergoing clinical Phase 3 research.
Huadong Medicine: The core commercial subsidiary of the medical aesthetics sector intends to liquidate and cancel

 Time of Update: 2022-01-10

In addition, Huadong Medicine's reply letter pointed out that it plans to enter the statutory liquidation stage after its business expires on December 31 in Ningbo, East China .
To seize the high value-added track of nucleoside APIs, a well-known pharmaceutical company completes a blockbuster acquisition

 Time of Update: 2022-01-09

> . After the reorganization is completed, Huadong Pharmaceutical will fully revitalize and make full use of Huachang Hi-Tech’s location advantages and pharmaceutical R&D and production background
This pharmaceutical company invested 100 million to participate in the bankruptcy and reorganization of the industrial microbial giant

 Time of Update: 2022-01-09

/>. According to data, Huachang Hi-Tech is a domestic industrial microbiology giant whose main business is the R&D and production of pharmaceutical intermediates and special chemicals <span
This pharmaceutical company declares the 7th indication for its innovative anti-tumor drug!

 Time of Update: 2022-01-09

falling again and again, analysts believe that in the future, pharmaceutical companies will only have more first-mover advantages if they are approved for more indications and further increase production capacity and commercialization capabilities
This pharmaceutical company has a bumper harvest, and 5 new drug listing applications have been approved during the year

 Time of Update: 2022-01-09

>At present, Avatinib has been successfully commercialized, and CStone Pharmaceuticals has signed strategic cooperation agreements with partners such as Sinopharm, Shanghai Meixin Health Technology, Beijing Yuanxin Technology, etc. , to greatly
Pharmaceutical giants report large-scale mergers and acquisitions!

 Time of Update: 2022-01-09

For this transaction, if the negotiations are successful, it means that Samsung will join the ranks of global biotech giants and expand its pharmaceutical business to areas other than biosimilars and contract production transactions .
2022 Shandong International Health Industry Expo Astragalus Product Exhibition

 Time of Update: 2022-01-09

DJK Shandong Health Expo, oriented to the global health consumer market, creates an international health industry rapid integration and development platform; Exhibitor recommendation: Chengdu Ximilai Technology Co.

Medicines Company News

The first cooperation project between Tianyan Pharmaceutical and Exelixis' original masked safe antibody conjugate drug has successfully reached a key milestone

 Time of Update: 2022-01-10

On December 23, 2021, Tianyan Pharmaceuticals announced that the first cooperation project with Exelixis reached at the beginning of the year for a precision masking safe antibody conjugate
Artemisinin-a gift from traditional Chinese medicine for thousands of years

 Time of Update: 2022-01-10

"The successful research and development of artemisinin-based antimalarial drugs is both the pride of China's medical and academic circles, and it is also our country's regret!" Artemisinin-based drugs are gifts from traditional Chinese medicine.
CD47 meets PD-L1, mutual achievement and exploration of infinite possibilities!

 Time of Update: 2022-01-10

In addition, Maiwei Biologics has also deployed 6MW3411, a bispecific antibody of PD-L1 and NK cell immune checkpoint, which is the first of its kind, and is expected to enter the clinical research phase in 2022 .
The critical illness protection rate is 96.0%, the first domestic adenovirus vector new crown vaccine global multi-center phase III clinical data announced

 Time of Update: 2022-01-10

HK) recently published a recombinant new coronavirus vaccine (type 5) in the international authoritative medical journal "The Lancet" Adenovirus vector) The final effective rate and interim safety analysis results of the global multi-center phase III clinical trial of Kevisa® .
Harbin Sanlian entered the administrative examination and approval stage with the imitation of the 4 types of flurbiprofen gel plaster reported for production

 Time of Update: 2022-01-10

Sales of terminal medicinal plasters in physical pharmacies in cities in China (unit: ten thousand yuan)　　Source: Mi Nei.
Discussion: Development of dissolution methods for oral solid preparations

 Time of Update: 2022-01-10

In the early stage of formulation development, when the dissolution test of tablets or capsules has not reached the standard, it may indicate the need to adjust the prescription and process, or the dissolution method .
Junshi Biologics subcutaneous injection preparation JS001sc injection clinical application is accepted

 Time of Update: 2022-01-10

Pre-clinical in vivo pharmacodynamic tests have shown that JS001sc has a significant tumor-inhibiting effect in animal models when administered by subcutaneous injection.
The latecomers are on top: the growth path of atorvastatin

 Time of Update: 2022-01-09

>In 1982, the clinical trial was completed in the United States . In 1987, it was approved by the FDA and became the first statin to be marketed under the trade name of Mevacor. </span
Guangzhou Pharmaceutical Group builds Macau's first GMP standard Chinese patent medicine factory

 Time of Update: 2022-01-09

with the same name and the same prescription and an improved Radix isatidis new medicine, which will be the first to realize the innovation of Baiyunshan Isatis root, made in Macau, and sold in Macau . </span
List of domestic drug R&D failure cases in 2021

 Time of Update: 2022-01-09

> . (2) On August 17, Zejing Pharmaceutical issued an announcement that Donafenib tosylate tablets in the treatment of stage III of advanced colorectal cancer above the second line showed that the median overall

Hot Products

Top Purity 99% N-(tert-Butoxycarbonyl)-4-piperidone with Best Price

CAS No.: 79099-07-3

Pharmaceutical Grade

$116/KG EXW

High Purity 3-OXO-4-PHENYL-BUTYRIC ACID ETHYL ESTER

CAS No.: 718-08-1

Pharmaceutical Grade

$108/KG EXW

price N-(tert-Butoxycarbonyl)-4-piperidone 99% white powder 99% White Syntheses Material Intermediates chem

CAS No.: 79099-07-3

ISO 9001

$80-100/KG EXW

Hot Tags

1 propanamine(7948)

1 bromopropane(4287)

2 2 dimethylbutane(4167)

1 heptanol(3955)

abilify medication(3330)

Hot Posts

Trending Keywords

contact media and communications

c battery contacts

davidson companies careers

c core company details

grace general hospital careers

australian catalog company

Chemical Exhibitions

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.